31 results about "Radiographic Contrast Agent" patented technology

Renal extraction fraction (EF) is determined through use of computed tomography (CT) measurements of arterial blood before and after injection of a radiographic contrast agent into the blood and CT measurements of renal vein blood after injection of the radiographic contrast agent.

The present invention discloses a radiographic contrasting agent containing multiple aromatic groups, each of which is substituted with at least three halogen atoms. The radiographic contrasting agent can initiate a polymerization process. The present invention also discloses a radio-opaque polymeric material that comprises a biodegradable polymer having at least one radiographic contrasting moiety covalently attached thereto. The radio-opaque polymeric material provides enhanced contrasting intensity in radiographic imaging. The radio-opaque polymeric material can be applied on at least a portion of one surface of a medical device. The radio-opaque polymeric material can also be used to construct a medical device, a component thereof, or a portion of a component thereof.

A radiocontrast agent for tau protein is provided. The agent is selectively and strongly bound to tau protein and its tangle found in brain diseases like Alzheimer's disease (AD). The agent is especially suitable to be used in PET imaging for brain diseases. Or, the agent can be used to inhibit tau protein overexpressive and, thus, stop the proceeding of brain disease.

The invention relates to a synthetic method of a non-ionic X-radiographic contrast agent iopamidol impurity C. according to the synthetic method, 5-amino-1,3-dibenzoyl dichloride is used as a starting material. The iopamidol impurity C can provides a qualified reference substance for quality control of iopamidol.

The invention locally delivers a chemotherapeutic or a radiographic contrast agent to an upper tract urothelial carcinoma (UTUC). The invention includes a balloon catheter with a working channel and aballoon placed into the ureter / renal pelvis via retrograde or antegrade ureteral access. The balloon is inflated to temporarily obstruct the ureter, and a formulation with a chemotherapeutic agent isinfused into the working channel of the catheter and allowed to dwell in the ureter / renal pelvis for a time sufficient to allow the formulation to adhere to and penetrate the urothelial wall. The formulations can be liposomal or non-liposomal formulations. At least a portion of the infused chemotherapeutic-agent formulation adheres to the urothelial wall while it is instilled and dwells in the ureter / renal pelvis. The methods of the invention can be performed as an adjuvant therapy to other methods of treating UTUC, including ureteroscopic ablation or resection of the tumor.

The invention discloses a method of using a ureter double saccule drainage tube. The method comprises the steps that after renal pelvis and renal calyces are dilated through conventional percutaneous hydronephrosis, a guide wire is imported to pass through a ureteral stenosis structure, the ureter double saccule drainage tube is imported through the guide wire; a radiocontrast agent is injected through an external connector of a fork-shaped injection base and is connected with a urine drainage cavity; when the ureteral stenosis structure is at the upper segment of the ureter, the second saccule is located in the ureteral stenosis structure, and the first saccule is located in the ureter; when the ureteral stenosis structure is at the lower segment of the ureter, the first saccule is located in the ureteral stenosis structure, and the second saccule is located in the ureter; the radiocontrast agent is injected through an external connector connected with the first saccule and the external connector connected with the second saccule of the fork-shaped injection base to fill the first saccule and the second saccule; the ureter double saccule drainage tube is fixed on the body surface. The ureter double saccule drainage tube has the advantages of being effective in draining urine, relieving hydronephrosis and expanding continuously the ureteral stenosis structure. The invention also discloses a double saccule drainage tube structure for the method of using the ureter double saccule drainage tube.